ClinicalTrials.gg
CompletedNCT04522167MAGELLAN-AMDUpdated Nov 13, 2025Results posted

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

A Phase 3 interventional study of FYB203 (Proposed aflibercept biosimilar) and Eylea® (Aflibercept) in Neovascular Age-related Macular Degeneration, sponsored by Bioeq GmbH. Completed at 66 sites in 9 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Bioeq GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
434
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
8th of 66
434 · median 55
Started
2020
with 1 other
Phase 3
18 of 66
1 open now
Registered
47th of 66
by date

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 8th largest by enrollment, is one of 2 that started in 2020, is one of 18 in phase 3, and was the 47th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years at Screening.
  • Male or female:

    • Male: A male patient must agree to use as defined in this protocol during the treatment period and for at least 4 weeks after the last dose of study treatment.
    • Female: A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

      1. Not a woman of (WOCBP), OR
      2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 4 weeks after the last dose of study treatment.
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Willingness and ability to undertake all scheduled visits and assessments.
  • Newly diagnosed choroidal neovascularization (CNV) lesion secondary to wet AMD

Exclusion criteria

Exclusion Criteria:

Patients are not eligible for the study if any of the following criteria apply:

  • Employees of clinical study sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized.
  • Study eye requiring immediate treatment.
  • Any prior treatment with VEGF agent or any products to treat AMD in either eye.
  • Uncontrolled ocular hypertension or glaucoma in the SE (defined as intraocular pressure [IOP] ≥ 30 mmHg, despite treatment with anti-glaucomatous medication).
  • Ocular disorders in the SE (i.e. retinal detachment, pre-retinal membrane of the macula or cataract with significant impact on VA) at the time of screening that may confound interpretation of study results and compromise VA.
  • Any concurrent intraocular condition in the SE (e.g. glaucoma, cataract, or diabetic retinopathy) that, in the opinion of the Investigator, would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results.
  • Use of other investigational drugs (excluding vitamins, minerals) within 30 days or 5 half lives from randomization, whichever is longer.
  • Any type of advanced, severe, or unstable disease, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.
  • Stroke or myocardial infarction within 6 months prior to randomization.
  • Known to the IMP (aflibercept or any component of the aflibercept formulation) or to drugs of similar chemical class or to fluorescein or any other component of fluorescein formulation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
434 participants (actual)

Study arms

  • Experimental
    FYB203 (Proposed aflibercept biosimilar)

    Patients will receive intravitreal (IVT) injections of FYB203 as detailed in the protocol.

    Drug: FYB203 (Proposed aflibercept biosimilar)

  • Active comparator
    Eylea® (Aflibercept)

    Patients will receive intravitreal (IVT) injections of Eylea® as detailed in the protocol.

    Drug: Eylea® (Aflibercept)

Interventions

  • Patients will receive 1 IVT injection of FYB203 in the study eye only every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.

  • Patients will receive 1 IVT injection of Eylea® in the study eye only every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.

06

What researchers measure

Primary outcomes

  1. Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With FYB203 or Eylea Compared to Baseline.

    Changes in Best Corrected Visual Acuity (BCVA) by ETDRS letters from the Baseline Visit (Visit 1) to Week 8 (Visit 3) were assessed. This involved measuring the number of letters a participant could correctly read using the study eye on the ETDRS chart. An increase in the number of ETDRS letters from baseline signifies an improvement in visual acuity of the study eye. The change from baseline was calculated as the observed post-baseline value minus the baseline value.

    Time frame: Week 8

Secondary outcomes

  1. Evaluate and Compare Functional Changes of the Retina by BCVA Over Time

    Change of BCVA by ETDRS letters over the whole study from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS

    Time frame: Through study completion, until Week 56 (Visit 9)

  2. Evaluate and Compare Changes in Foveal Center Point (FCP) Retinal Thickness

    Change from Baseline Visit (Visit 1) in foveal center point FCP retinal thickness to Week 4 (Visit 2), Week 24 (Visit 5) and Week 56 (Visit 9) - FAS

    Time frame: Through study completion, until Week 56 (Visit 9)

  3. Evaluate and Compare the Proportion of Patients Who Gain or Lose ≥ 5, 10, and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters Compared to Baseline

    Proportion of patients who gain or lose ≥ 5, 10, or 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS

    Time frame: Through study completion, until Week 56 (Week 9)

  4. Evaluate and Compare the Absence of Disease Activity (Fluid-free Macula) Over Time

    Percentage of patients with fluid-free macula at Baseline (Visit 1), Week 24 (Visit 5), Week 56 (Visit 9) - FAS

    Time frame: Through study completion, until Week 56 (Visit 9)

  5. Evaluate and Compare Systemic Free Aflibercept Concentrations in a Subgroup of up to 60 Patients (up to 30 Per Arm)

    Systemic concentrations (close to maximum concentration \[Cmax\]) of free aflibercept in a subgroup at selected sites - PKS: \- 48 hours after the 3rd dose (Visit 3a)

    Time frame: At Baseline and Visit 3a (48 hours after the 3rd dose)

  6. Evaluate and Compare Change in Vision-related Functioning and Well-being Measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)

    Change from Baseline Visit (Visit 1) in vision-related functioning and well-being measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS. The NEI VFQ-25 includes 12 subscales (e.g., general vision, ocular pain, driving, peripheral vision) scored from 0 to 100, where higher scores indicate better functioning. Subscales are averaged to produce a composite score, excluding the general health subscale. Both subscale and composite scores range from 0 (worst) to 100 (best), representing the percentage of the highest possible score achieved.

    Time frame: Through study completion, until Week 56 (Visit 9)

  7. Evaluate and Compare the Immunogenic Profile (Anti-drug Antibodies [ADAs]) in Serum

    Number of patients with anti-drug antibodies (ADAs) at Baseline (Visit 1), Week 24 (Visit 5) and Week 56 (Visit 9) - SAF

    Time frame: Through study completion, until Week 56 (Visit 9)

  8. Frequency of Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Frequency of local and systemic adverse events (AEs) and serious adverse events (SAEs) - SAF

    Time frame: Through study completion, until Week 56 (Visit 9)

07

Results

Posted Nov 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
Started215219
Completed196206
Not completed1913

Outcome measures

PrimaryEvaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With FYB203 or Eylea Compared to Baseline.

Changes in Best Corrected Visual Acuity (BCVA) by ETDRS letters from the Baseline Visit (Visit 1) to Week 8 (Visit 3) were assessed. This involved measuring the number of letters a participant could correctly read using the study eye on the ETDRS chart. An increase in the number of ETDRS letters from baseline signifies an improvement in visual acuity of the study eye. The change from baseline was calculated as the observed post-baseline value minus the baseline value.

Time frame:
Week 8
Reported as:
Least squares mean · letters
Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With FYB203 or Eylea Compared to Baseline.
lettersFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With FYB203 or Eylea Compared to Baseline.6.6 ± 0.735.6 ± 0.73
Statistical analysis
  • FYB203 (Proposed Aflibercept Biosimilar) vs Eylea® (Aflibercept) · Ls mean difference: 1.0 · 90.4% CI -0.3 to 2.2
SecondaryEvaluate and Compare Functional Changes of the Retina by BCVA Over Time

Change of BCVA by ETDRS letters over the whole study from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS

Time frame:
Through study completion, until Week 56 (Visit 9)
Reported as:
Mean · letters
Evaluate and Compare Functional Changes of the Retina by BCVA Over Time
lettersFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
to Week 24 (Visit 5)7.0 ± 9.456.6 ± 9.51
to Week 56 (Visit 9)8.3 ± 10.376.6 ± 11.47
SecondaryEvaluate and Compare Changes in Foveal Center Point (FCP) Retinal Thickness

Change from Baseline Visit (Visit 1) in foveal center point FCP retinal thickness to Week 4 (Visit 2), Week 24 (Visit 5) and Week 56 (Visit 9) - FAS

Time frame:
Through study completion, until Week 56 (Visit 9)
Reported as:
Mean · μm
Evaluate and Compare Changes in Foveal Center Point (FCP) Retinal Thickness
μmFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
to Week 4 (Visit 2)-163.9 ± 142.17-168.4 ± 126.36
to Week 24 (Visit 5)-165.9 ± 174.98-172.4 ± 153.00
to Week 56 (Visit 9)-188.4 ± 181.08-202.4 ± 156.96
SecondaryEvaluate and Compare the Proportion of Patients Who Gain or Lose ≥ 5, 10, and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters Compared to Baseline

Proportion of patients who gain or lose ≥ 5, 10, or 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS

Time frame:
Through study completion, until Week 56 (Week 9)
Reported as:
Count of participants · Participants
Evaluate and Compare the Proportion of Patients Who Gain or Lose ≥ 5, 10, and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters Compared to Baseline
ParticipantsFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
to Week 24 (Visit 5) — ≥ 15 letters (gain 15 or more)4538
to Week 24 (Visit 5) — ≥ 10 and < 15 letters (gain 10-14)4139
to Week 24 (Visit 5) — ≥ 5 and < 10 letters (gain 5-9)4147
to Week 24 (Visit 5) — > -5 and < 5 letters (gain or loss up to 4)5258
to Week 24 (Visit 5) — > -10 and ≤ -5 letters (loss 5-9)1213
to Week 24 (Visit 5) — > -15 and ≤ -10 letters (loss 10-14)62
to Week 24 (Visit 5) — ≤ -15 letters (loss 15 or more)46
to Week 56 (Visit 9) — ≥ 15 letters (gain 15 or more)5249
to Week 56 (Visit 9) — ≥ 10 and < 15 letters (gain 10-14)4336
to Week 56 (Visit 9) — ≥ 5 and < 10 letters (gain 5-9)3439
to Week 56 (Visit 9) — > -5 and < 5 letters (gain or loss up to 4)3948
to Week 56 (Visit 9) — > -10 and ≤ -5 letters (loss 5-9)1213
to Week 56 (Visit 9) — > -15 and ≤ -10 letters (loss 10-14)67
to Week 56 (Visit 9) — ≤ -15 letters (loss 15 or more)29
SecondaryEvaluate and Compare the Absence of Disease Activity (Fluid-free Macula) Over Time

Percentage of patients with fluid-free macula at Baseline (Visit 1), Week 24 (Visit 5), Week 56 (Visit 9) - FAS

Time frame:
Through study completion, until Week 56 (Visit 9)
Reported as:
Count of participants · Participants
Evaluate and Compare the Absence of Disease Activity (Fluid-free Macula) Over Time
ParticipantsFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
Baseline (Visit 1) — Assessment / Response = Yes00
Baseline (Visit 1) — Assessment / Response = No214217
Week 24 (Visit 5) — Assessment / Response = Yes7165
Week 24 (Visit 5) — Assessment / Response = No127135
Week 56 (Visit 9) — Assessment / Response = Yes79100
Week 56 (Visit 9) — Assessment / Response = No10898
SecondaryEvaluate and Compare Systemic Free Aflibercept Concentrations in a Subgroup of up to 60 Patients (up to 30 Per Arm)

Systemic concentrations (close to maximum concentration \[Cmax\]) of free aflibercept in a subgroup at selected sites - PKS: \- 48 hours after the 3rd dose (Visit 3a)

Time frame:
At Baseline and Visit 3a (48 hours after the 3rd dose)
Reported as:
Mean · ng/mL
Evaluate and Compare Systemic Free Aflibercept Concentrations in a Subgroup of up to 60 Patients (up to 30 Per Arm)
ng/mLFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
Baseline (Visit 1)2.000 ± 0.00002.000 ± 0.0000
Visit 3a (48h after 3rd dose)122.166 ± 30.5161120.112 ± 28.9556
SecondaryEvaluate and Compare Change in Vision-related Functioning and Well-being Measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)

Change from Baseline Visit (Visit 1) in vision-related functioning and well-being measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS. The NEI VFQ-25 includes 12 subscales (e.g., general vision, ocular pain, driving, peripheral vision) scored from 0 to 100, where higher scores indicate better functioning. Subscales are averaged to produce a composite score, excluding the general health subscale. Both subscale and composite scores range from 0 (worst) to 100 (best), representing the percentage of the highest possible score achieved.

Time frame:
Through study completion, until Week 56 (Visit 9)
Reported as:
Mean · score points
Evaluate and Compare Change in Vision-related Functioning and Well-being Measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)
score pointsFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
to Week 24 (Visit 5)3.8 ± 11.061.8 ± 10.97
to Week 56 (Visit 9)3.8 ± 12.221.7 ± 12.46
SecondaryEvaluate and Compare the Immunogenic Profile (Anti-drug Antibodies [ADAs]) in Serum

Number of patients with anti-drug antibodies (ADAs) at Baseline (Visit 1), Week 24 (Visit 5) and Week 56 (Visit 9) - SAF

Time frame:
Through study completion, until Week 56 (Visit 9)
Reported as:
Count of participants · Participants
Evaluate and Compare the Immunogenic Profile (Anti-drug Antibodies [ADAs]) in Serum
ParticipantsFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
Week 1 (Baseline) — Positive43
Week 1 (Baseline) — Negative209201
Week 24 (Visit 5) — Positive41
Week 24 (Visit 5) — Negative191192
Week 56 (Visit 9) — Positive52
Week 56 (Visit 9) — Negative189190
SecondaryFrequency of Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)

Frequency of local and systemic adverse events (AEs) and serious adverse events (SAEs) - SAF

Time frame:
Through study completion, until Week 56 (Visit 9)
Reported as:
Count of participants · Participants
Frequency of Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsFYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)
SAEs1928
local AEs, study eye6775
local AEs, fellow eye4548
systemic AEs124113

Adverse events

Collected over All AEs reported until the final end of study visit at week 56 are included.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FYB203 (Proposed Aflibercept Biosimilar), Systemic AE4/215 (1.9%)17/215 (7.9%)56/215 (26%)
Eylea® (Aflibercept), Systemic AE1/218 (0.5%)23/218 (10.6%)46/218 (21.1%)
FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Study Eye0/215 (0%)2/215 (0.9%)44/215 (20.5%)
Eylea® (Aflibercept), Ocular AE, Study Eye0/218 (0%)2/218 (0.9%)49/218 (22.5%)
FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Fellow Eye0/215 (0%)0/215 (0%)37/215 (17.2%)
Eylea® (Aflibercept), Ocular AE, Fellow Eye0/218 (0%)3/218 (1.4%)32/218 (14.7%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventFYB203 (Proposed Aflibercept Biosimilar), Systemic AEEylea® (Aflibercept), Systemic AEFYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Study EyeEylea® (Aflibercept), Ocular AE, Study EyeFYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Fellow EyeEylea® (Aflibercept), Ocular AE, Fellow Eye
COVID-19Infections and infestations4/2151/2180/2150/2180/2150/218
Cardiac failureCardiac disorders2/2151/2180/2150/2180/2150/218
COVID-19 pneumoniaInfections and infestations1/2152/2180/2150/2180/2150/218
AppendicitisInfections and infestations0/2152/2180/2150/2180/2150/218
PneumoniaInfections and infestations1/2151/2180/2150/2180/2150/218
BronchitisInfections and infestations1/2150/2180/2150/2180/2150/218
Coronavirus infectionInfections and infestations1/2150/2180/2150/2180/2150/218
Gallbladder empyemaInfections and infestations1/2150/2180/2150/2180/2150/218
Toxic shock syndromeInfections and infestations1/2150/2180/2150/2180/2150/218
UrosepsisInfections and infestations1/2150/2180/2150/2180/2150/218
Most frequent other events
Showing 10 of 15
Most frequent other events
EventFYB203 (Proposed Aflibercept Biosimilar), Systemic AEEylea® (Aflibercept), Systemic AEFYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Study EyeEylea® (Aflibercept), Ocular AE, Study EyeFYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Fellow EyeEylea® (Aflibercept), Ocular AE, Fellow Eye
Neovascular age-related macular degenerationEye disorders0/2150/2187/2157/21822/21524/218
COVID-19Infections and infestations15/21517/2180/2150/2180/2150/218
HypertensionVascular disorders15/2159/2180/2150/2180/2150/218
Conjunctival haemorrhageEye disorders0/2150/2184/21514/2181/2150/218
NasopharyngitisInfections and infestations10/2156/2180/2150/2180/2150/218
OsteoarthritisMusculoskeletal and connective tissue disorders9/2151/2180/2150/2180/2150/218
Intraocular pressure increasedInvestigations0/2150/2187/2159/2182/2151/218
CataractEye disorders0/2150/2188/2157/2187/2154/218
Visual acuity reducedEye disorders0/2150/2187/2154/2182/2152/218
HeadacheNervous system disorders4/2157/2180/2150/2180/2150/218

Baseline characteristics

Safety Analysis Set (SAF)

Age, Continuous
Age, Continuous(years)FYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)Total
Mean73.7 ± 7.7273.3 ± 7.7073.5 ± 7.71
Age, Customized
Age, Customized(Participants)FYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)Total
Age, Categorical — Between 18 and 64 years172542
Age, Categorical — Between 65 and 84 years181180361
Age, Categorical — >= 85 years171330
Sex: Female, Male
Sex: Female, Male(Participants)FYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)Total
Female121127248
Male9491185
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)Total
Hispanic or Latino358
Not Hispanic or Latino212213425
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)Total
American Indian or Alaska Native000
Asian171633
Native Hawaiian or Other Pacific Islander000
Black or African American000
White197201398
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)FYB203 (Proposed Aflibercept Biosimilar)Eylea® (Aflibercept)Total
Bulgaria101121
Czechia343569
Hungary343468
Israel6612
Italy9918
Japan171633
Poland374077
Russia353671
Ukraine333164
08

Study locations

66 sites
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Stara Zagora, Bulgaria
  • Research Site
    Hradec Králové, Czechia
  • Research Site
    Ostrava, Czechia
  • Research Site
    Pardubice, Czechia
  • Research Site
    Prague, Czechia
  • Research Site
    Sokolov, Czechia
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Pécs, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Székesfehérvár, Hungary
  • Research Site
    Tatabánya, Hungary
  • Research Site
    Zalaegerszeg, Hungary
  • Research Site
    Haifa, Israel
  • Research Site
    Jerusalem, Israel
  • Research Site
    Kfar Saba, Israel
  • Research Site
    Petah Tikva, Israel
  • Research Site
    Rehovot, Israel
  • Research Site
    Rishon LeZiyyon, Israel
  • Research Site
    Tel Aviv, Israel
  • Research Site
    Bologna, Italy
  • Research Site
    Florence, Italy
  • Research Site
    Milan, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Rozzano, Italy
  • Research Site
    Udine, Italy
  • Research Site
    Akita, Japan
  • Research Site
    Amagasaki, Japan
  • Research Site
    Asahikawa, Japan
  • Research Site
    Chiyoda City, Japan
  • Research Site
    Chūō, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Fukushima, Japan
  • Research Site
    Hamamatsu, Japan
  • Research Site
    Himeji, Japan
  • Research Site
    Hirakata, Japan
  • Research Site
    Kita-ku, Japan
  • Research Site
    Kurume, Japan
  • Research Site
    Meguro City, Japan
  • Research Site
    Nagasaki, Japan
  • Research Site
    Nagoya, Japan
  • Research Site
    Sapporo, Japan
  • Research Site
    Shinjuku-Ku, Japan
  • Research Site
    Suita, Japan
  • Research Site
    Toride, Japan
  • Research Site
    Yokosuka, Japan
  • Research Site
    Bielsko-Biala, Poland
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Olsztyn, Poland
  • Research Site
    Tarnów, Poland
  • Research Site
    Warsaw, Poland
  • Research Site
    Chelyabinsk, Russia
  • Research Site
    Kazan', Russia
  • Research Site
    Moscow, Russia
  • Research Site
    Novosibirsk, Russia
  • Research Site
    Saint Petersburg, Russia
  • Research Site
    Kharkiv, Ukraine
  • Research Site
    Kherson, Ukraine
  • Research Site
    Kropyvnytskyi, Ukraine
  • Research Site
    Lutsk, Ukraine
  • Research Site
    Odesa, Ukraine
  • Research Site
    Poltava, Ukraine
  • Research Site
    Zaporizhzhya, Ukraine
09

References and documents

Publications

  • Balser S, Capsius B, Hole R, Papp A, Preissinger N, Rozenknop A, Tiko T. Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration. BMJ Open Ophthalmol. 2026 Jan 5;11(1):e002398. doi: 10.1136/bmjophth-2025-002398. PubMed 41494750 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jun 2022, 23 months.

Results were first posted in Nov 2025, 3 years 4 months after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 23 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 21, 2020
StartActual
Jul 21, 2020
Primary completionActual
Jun 23, 2022
CompletionActual
May 18, 2023
Results first posted
Nov 13, 2025
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04522167
Lead sponsor
Bioeq GmbH
Responsible party
Sponsor
First posted
Aug 21, 2020
Start date
Jul 21, 2020
Primary completion
Jun 23, 2022
Completion
May 18, 2023
Results posted
Nov 13, 2025
Last update
Nov 13, 2025

Study contacts

Study Official
study director · Bioeq GmbH

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion